Antimycobacterial activities of riminophenazines

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue 5, 1999, Pages 615-623

  Redd, Venkata M ^a   O'Sullivan, John F ^b   Gangadharam, Pattisapu R J ^c  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; ISONIAZID; TUBERCULOSTATIC AGENT;

DRUG EFFICACY; DRUG METABOLISM; HUMAN; LEPROSY; LEPROSY CONTROL; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; PHAGOCYTE; REVIEW; SIDE EFFECT; SKIN PIGMENTATION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CLOFAZIMINE; HUMANS; LEPROSTATIC AGENTS; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; PHENAZINES;

EID: 0032896583     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.5.615     Document Type: Review

References (73)

1. Barry. V. C. ( 1974). The development of chemotherapeutic agent for tuberculosis. In Chemotherapy of Tuberculosis (Barry, V. C., Ed.), pp. 46-64. Butterworths, London.
2. Barry, V. C. (1969). Synthetic phenazine derivatives and mycobacterial diseases: a twenty year investigation. Scientific Proceedings of Royal Dublin Society (Series A) 3, 153-70.
3. Nolan, T. J., Algar, J., McCann, P., Monahan, W. A. & Nolan, N. (1948). The chemical constituents of lichens found in Ireland: Buellia canescens. Part 3. Scientific Proceedings of Royal Dublin Society 24, 319-34.
4. Barry, V. C., Belton, J. G., Conalty, M. L. & Twomey, D. (1948). Antitubercular activity of oxidation products of substituted o-phenylene diamines. Nature 162, 622-3.
5. Barry, V. C., Buggle, K., Byrne, J., Conalty, M. L. & Winder, F. (1960). Absorption, distribution and retention of the imino compounds in the experimental animals. Irish Journal of Medical Sciences 416, 345-52.
6. Barry, V. C. & Conalty, M. L. (1965). The antimycobacterial activity of B663. Leprosy Reviews 36, 3-7.
7. Vischer, W. A. (1969). The experimental properties of G30320 (B663) - a new antileprotic agent. Leprosy Reviews 40, 107-10.
8. Schmidt, L. H., Hoffman, R. & Jolly, P. N. (1955). Induced pulmonary tuberculosis in the rhesus monkey: its usefulness in evaluating chemotherapeutic agents. Proceedings of 14th Conference V.A-A.F. Tuberculosis, pp. 226-31. Atlanta, GA. Veteran Administration: Army: Navy, USA.
9. Barry, V. C. & Conalty, M. L. (1958). Antituberculosis activity in the phenazine series. American Review of Tuberculosis 78, 62-73.
10. Browne, S. G. & Hogerzeh, L. M. (1962). B663 in the treatment of leprosy: a preliminary report of a pilot trial. Leprosy Reviews 33, 6-10.
11. Ji, B., Lounis, N., Truffot-Pernot, C. & Grosset, J. (1994). Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mice model. Antimicrobial Agents and Chemotherapy 38, 2521-9.
12. Schultz, E. J. (1971). Forty four months experience in the treatment of leprosy with clofazimine (Lamprene (R)). Leprosy Reviews 42, 178-87.
13. World Health Organization. (1982). Chemotherapy of leprosy for control programs; report of WHO study groups. WHO Technical Report Series 675, 7-33.
14. Yawalkar, S. J. & Vischer, W. (1979). Lamprene (clofazimine) in leprosy. Leprosy Reviews 50, 135-44.
15. Snider, D. E., Hopewell, P. C., Mills, J. & Reichman, L. B. (1987). Mycobacterioses and the acquired immunodeficiency syndrome. American Review of Respiratory Diseases 136, 492-6.
16. Gangadharam, P. R. J. & Candler, E. R. (1977). Activity of some antileprosy compounds against Mycobacterium intracellulare in vitro. American Review of Respiratory Diseases 115, 705-7.
17. Gangadharam, P. R. J., Pratt, P. F., Damle, P. B. & Davidson, P. T. (1981). Dynamic aspects of the activity of clofazimine against Mycobacterium intracellulare. Tubercle 62, 201-6.
18. Garrelts, J. C. (1991). Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. DICP 25, 525-31.
19. Young, L. S. (1988). Mycobacterium avium complex infection. Journal of Infectious Diseases 157, 863-7.
20. Banerjee, D. K. & Holmes, I. B. (1976). In vitro and in vivo studies of the action of rifampicin, clofazimine and B1912 on Mycobacterium marinum. Chemotherapy 22, 242-52.
21. Revill, W. D. L., Morrow, R. H., Pike, M. C. & Ateng, J. (1973). A controlled trial of treatment of Mycobacterium ulcerans infection with clofazimine. Lancet 2, 873-7.
22. Runyon, E. H. (1965). Pathogenic mycobacteria. Advances in Tuberculosis Research 14, 235-87.
23. O'Connor, R., O'Sullivan, J. F. & O'Kennedy, R. (1995). The pharmacology, metabolism and chemistry of clofazimine. Drug Metabolism Reviews 27, 591-614.
24. Barry, V. C., Belton, J. G., Conalty, M. L., Denneny, J. M., Edward, D. W., O'Sullivan, J. F. et al. (1957). A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature 179, 1013-15.
25. Morrison, N. E. & Marley, G. M. (1976). The mode of action of clofazimine DNA binding studies. International Journal of Leprosy 44, 133-4.
26. + adenosine triphosphatase activity of human lymphocytes by a lysophospholipase dependent mechanism. Biochemical Pharmacology 46, 2029-38.
27. 2 activity and superoxide generation. Journal of Infectious Diseases 167, 899-904.
28. Van Rensburg, C. J., Joone, G. K., O'Sullivan, J. F. & Anderson, R. (1992). Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Antimicrobial Agents and Chemotherapy 36, 2729-35.
29. 2-mediated oxidative and nonoxidative mechanisms. Cancer Research 53, 318-23.
30. Wadee, A. A., Kuschke, R. H., Dooms, T. G. & Anderson, R. (1995). The pro-oxidative riminophenazine B669 neutralizes the inhibitory effects of Mycobacterium tuberculosis on phagocyte antimicrobial activity. International Journal of Immunopharmacology 17, 849-56.
31. Zeis, B. M. & Anderson, R. (1986). Clofazimine-mediated stimulation of prostaglandin synthesis and free radical production as novel mechanisms of drug-induced immunosuppression. International Journal of Immunopharmacology 8, 731-9.
32. Shepard, C. C. (1969). Minimal effective dosages in mice of clofazimine (B663) and of ethionamide against Mycobacterium eprae (34162). Proceedings of Society for Experimental Biology and Medicine 132, 120-4.
33. Browne, S. G., Harman, D. J., Waudby, H. & McDougall, A. C. (1981). Clofazimine (Lamprene (R)) in the treatment of lepromatous leprosy in the United Kingdom. A 12 year review of 31 cases. 1966-1978. International Journal of Leprosy 49, 167-76.
34. Hastings, R. C. & Trautman, J. R. (1968). B663 in lepromatous leprosy. Effect in erythema nodosum leprosum. Leprosy Reviews 39, 3-7.
35. Franzblau, S. G. & O'Sullivan, J. F. (1988). Structure-activity relationships of selected phenazines against Mycobacterium leprae in vitro. Antimicrobial Agents and Chemotherapy 32, 1583-5.
36. Freerksen, E. & Seydel, J. K. (1992). Critical comments on the treatment of leprosy and other mycobacterial infections with clofazimine. Arzneimittelforsching 42, 1243-5.
37. Van Landingham, R. M., Walker, L. L., O'Sullivan, J. F. & Shinnick, T. M. (1993). Activity of phenazine analogues against Mycobacterium leprae infections in mice. International Journal of Leprosy 61, 406-14.
38. Franzblau, S. G., White, K. E. & O'Sullivan, J. F. (1989). Structure-activity relationships of tetramethylpiperidine-substituted phenazines against Mycobacterium leprae in vitro. Antimicrobial Agents and Chemotherapy 33, 2004-5.
39. Gangadharam, P. R. J., Ashtekar, D. & O'Sullivan, J. F. (1992). In vitro, in vivo, and intracellular chemotherapeutic activity of B746, a clofazimine analogue against Mycobacterium avium complex. Tubercle and Lung Diseases 73, 192-9.
40. Jagannath, C., Reddy, M. V., Kailasam, S., O'Sullivan, J. F. & Gangadharam, P. R. J. (1995). Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis: in vitro, intracellular, and in vivo studies. American Journal of Respiratory and Critical Care Medicine 151, 1083-6.
41. Reddy, V. M., Nadadhur, G., Daneluzzi, D., O'Sullivan, J. F. & Gangadharam, P. R. J. (1996). Antituberculosis activities of clofazimine and its new analogues B4154 and B4157. Antimicrobial Agents and Chemotherapy 40, 633-6.
42. Gangadharam, P. R. J., Pratt, P. F., Damle, P. B. & Davidson, P. T. (1979). Antimycobacterial activity of clofazimine (B663) against M. intracellulare. Bulletin of International Union against Tuberculosis 54, 348-50.
43. Lindholm-Levy, P. J. & Heifets, L. (1988). Clofazimine and other riminocompounds: minimal inhibitory and minimal bactericidal concentrations at different pHs for Mycobacterium avium complex. Tubercle 69, 179-86.
44. Fattorini, L., Li, B., Piersimoni, C., Tortoli, E., Xiao, Y., Santoro, C. et al. (1995). In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacgerium avium. Antimicrobial Agents and Chemotherapy 39, 680-5.
45. Rastogi, N., Bauriaud, R. M., Bourgoin, A., Carbonelle, B., Chippaux, C., Gevaudan, M. J. et al. (1995). French multi center study involving eight test sites for radiometric determination of activities of 10 antimicrobial agents against Mycobacterium avium complex. Antimicrobial Agents and Chemotherapy 39, 638-44.
46. Rastogi, N., Labrousse, V. & Bryskier, A. (1995). Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages. Antimicrobial Agents and Chemotherapy 39, 976-8.
47. Yajko, D. M., Sanders, C. A., Madej, J. J., Cawthon, V. L. & Hadley, W. K. (1996). In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium. Antimicrobial Agents and Chemotherapy 40, 743-49.
48. Gangadharam, P. R. J. & Parikh, K. (1992). In vivo activity of streptomycin and clofazimine against established infection of Mycobacterium avium complex in beige mice. Journal of Antimicrobial Chemotherapy 30, 833-8.
49. Gangadharam, P. R. J., Perumal, V. K., Jairam, B. T., Rao, P. N., Nguyen, A. K., Farhi, D. C. et al. (1987). Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections. American Review of Respiratory Diseases 136, 329-33.
50. Gangadharam, P. R. J., Perumal, V. K., Podapati, N. R., Kesavalu, L. & Iseman, M. D. (1988). In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice. Antimicrobial Agents and Chemotherapy 32, 1400-3.
51. Klemens, S. P., DeStefano, M. S. & Cynamon, M. H. (1992). Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Antimicrobial Agents and Chemotherapy 36, 2413-17.
52. Gangadharam, P. R. J. & Reddy, M. V. (1995). Carryover of clofazimine into culture media. Antimicrobial Agents and Chemotherapy 39, 1388-9.
53. Davidson, P. T., Fernandez, E., Goble, M. & Gangadharam, P. R. J. (1979). Evaluation of the role of clofazimine (B663) for the treatment of Mycobacterium intracellulare disease. American Review of Respiratory Diseases 119, Suppl., 398.
54. Abrams, D. I., Mitchell, T. F., Child, C. C., Shiboski, S. C., Brosgart, C. L. & Mass, M. M. 1993). Clofazimine as prophylaxis for disseminated Mycobacterium avium complex infection in AIDS. Journal of Infectious Diseases 167, 1459-63.
55. Armstrong, D., Gold, J. W. M., Dyjanski, I., Whimbley, E., Polsky, B., Hawkins, C. et al. (1985). Treatment of infections in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine 103, 738-43.
56. Hawkins, C. C., Gold, J. W. M., Whimbey, E., Kiehn, T. E., Brannon, P., Cammarata, R. et al. (1986). Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine 105, 184-8.
57. Horsburgh, C. R., Mason, U. G., Farhi, D. C. & Iseman, M. D. (1985). Disseminated infection with Mycobacterium avium-intracellulare. A report of 13 cases and a review of the literature Medicine 64, 36-48.
58. Woods, G. L. & Washington, J. A. (1987). Mycobacteria other than Mycobacterium tuberculosis: review of the microbiologic and clinical aspects. Reviews of Infectious Diseases 9, 275-94.
59. Masur, H., Tuazon, G., Gill, V., Grimes, G., Baird, B., Fauci, A. S. et al. (1987). Effect of combined clofazimine and ansamycin therapy on Mycobacterium avium-intracellulare bacteraemia in patients with AIDS. Journal of Infectious Diseases 155, 127-9.
60. O'Brien, R. J., Lyle, M. A. & Snider, D. E. (1987). Rifabutin (ansamycin, LM427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Reviews of Infectious Diseases 9, 519-30.
61. Desikan, K. V. & Balakrishnan, S. (1976). Tissue levels of clofazimine in a case of leprosy. Leprosy Reviews 47, 107-13.
62. Feng, P. C. C., Fenselau, C. & Jacobson, R. R. (1989). Metabolism of clofazimine in leprosy patients. Drug Metabolism and Disposition 9, 521-4.
63. Schaad-Lanyi, Z., Dieterle, W., Dubois, J. P., Theobald, W. & Vischer, W. (1987). Pharmacokinetics of clofazimine in healthy volunteers. International Journal of Leprosy 55, 9-15.
64. Levy, L. (1974). Pharmacologic studies of clofazimine. American Journal of Tropical Medicine and Hygiene 23, 1097-9.
65. -) from hamster peritoneal macrophages. Bulletin of International Union against Tuberculosis 57, 32 (abstract).
66. 2 but not protein kinase C in the pro-oxidative interactions of clofazimine with human phagocytes. Biochemical Pharmacology 37, 4635-41.
67. Savage, J. E., O'Sullivan, J. F., Zeis, B. M. & Anderson, R. (1989). Investigation of the structural properties of dihydrophenazines which contribute to their pro-oxidative interactions with human phagocytes. Journal of Antrimicrobial Chemotherapy 23, 691-700.
68. Wadee, A. A., Cohen, J. D. & Rabson, A. R. (1987). Gamma interferon reverses inhibition of leukocyte bactericidal activity by a 25-kilodalton fraction from Mycobacterium tuberculosis. Infection Immunity 55, 2777-82.
69. Wadee, A. A., Anderson, R. & Rabson, A. R. (1988). Clofazimine reverses the inhibitory effects of Mycobacterium tuberculosis derived factors on phagocyte intracellular killing mechanisms. Journal of Antimicrobial Chemotherapy 21, 65-74.
70. Thomsen, K. & Rothenborg, H. W. (1979). Clofazimine in the treatment of pyoderma gangrenosum. Archives of Dermatology 115, 851-2.
71. Mackey, J. P. & Barnes, J. (1974). Clofazimine in the treatment of discoid lupus erythematosus. British Journal of Dermatology 91, 93-6.
72. Bor, S. (1973). Clofazimine (Lamprene (R)) in the treatment of vitiligo. South African Medical Journal 47, 1451-4.
73. 2 by human polymorphonuclear leucocytes in vitro. Antimicrobial Agents and Chemotherapy 27, 257-62.